We have previously described an antigenspecific I-Ad-restricted T-cell hybridoma, AM.l, that constitutively releases an antigen-specific immunoregulatory activity into supernatants. Using retrovirally mediated gene transfer, we have found that transfer of the T-cell receptor a chain (TCRa) gene from Al.l to a number of other T-cell hybridomas effectively transferred the ability to produce the activity.
The heterodimeric T-cell receptor (TCR) has been demonstrated to recognize a ligand composed of an antigenic peptide in association with a major histocompatibility complex molecule (1) . Studies in which the TCR a and / chain (TCRa and TCRP3) genes were transferred from one T cell to another have shown that these two polypeptide chains are both necessary and sufficient for recognition of the ligand (2, 3) . Although some studies suggest that the TCR a and TCR /3 variable regions (Va and Vp, respectively) are skewed toward recognition of antigen and major histocompatibility complex, respectively (4) (5) (6) , other studies suggest that recognition is an emergent property of the entire receptor (7, 8) . It is possible that these divergent views represent differences in the particular TCRs and ligands studied.
Some recent studies (9, 10) suggest that, in addition to its role in T-cell recognition of the antigen and major histocompatibility complex, the TCR might have an immunoregulatory function when shed or released from cells. We have examined this possibility in a number of ways. This laboratory has reported (11) that a helper T-cell hybridoma, A1.1, specific for a synthetic polypeptide antigen, poly-18, plus I-Ad constitutively releases a poly-18-specific immunoregulatory activity, detected by an in vitro assay (12) . The fine antigenic specificity of this cell-free activity corresponded to the specificity of the AM.1 TCR (12, 13) . This antigen-specific regulatory activity was bound and eluted from a pan-specific anti-TCRa monoclonal antibody (mAb) and resolved by SDS/PAGE as a 46-kDa protein (13) . The activity was not bound by anti-TCRf3, anti-TCR Vp, or anti-CD3E monoclonal antibodies (13) . The relationship to the TCR was further established by the use of antisense oligonucleotides corresponding to TCR Va that inhibited the production of the soluble regulatory activity (14) . Here, we report that retroviral gene transfer of the Al.1 TCRa gene, but not the TCR/3 gene, into a number ofT-cell lines results in the transfer ofthe ability to produce the regulatory activity. These results implicate the TCRa as the source of the activity we observe.
MATERIALS AND METHODS Animals. C57BL/10 and C57BL/6 mice were bred and housed in our facility at the University of Alberta Retroviral Gene Transfer. All of the retroviral vectors used in this study are derivatives of the N2 vector (19) . The A1.1 TCRa and TCRf3 cDNAs will be described elsewhere (P.
Kilgannon and A.F., unpublished data). In brief, the A1.1 TCRa cDNA uses the Val.2 (20) and JaTA65 a-chainjoining region (20) and the A1.1 TCRj3 cDNA uses the V/86 (21) , D.82 p-chain diversity region (22) , and J/82.7 /3-chainjoining region (23) Assay for Antigen-Specific Regulatory Activity. To assay for A1.1-derived antigen-specific regulatory activity, a simple system was employed (12) (13) (14) . Spleen cells (1 x 107 cells) from C57BL/6 or C57BL/10 mice were placed into 1-ml cultures in RPMI 1640 medium with 10% fetal calf serum. Each culture received 50 ,ul of 1% SRBCs coupled with poly-18 or a substituted polypeptide. Suppressive activity was assessed by adding hybridoma supernatant with or without an "accessory supernatant," 10-15% (vol/vol), to the cultures. This accessory supernatant was prepared from cultures of murine T cells from animals immunized with SRBCs, followed by absorption of the supernatant with SRBCs (12, 13) . The cultures were incubated at 370C in humidified 92% air/8% CO2 and anti-SRBC plaque-forming cells (PFC) were assessed 5 days later. In all of the experiments shown, neither the T-cell hybridoma supernatants nor the accessory supernatant significantly affected the immune response when added alone (data not shown). All control and experimental cultures described herein contain accessory supernatant (results without accessory supernatant are not shown).
Direct Binding of Biotin-Coijugated Peptides to T-CellDerived Protein. The peptides EYK(EYA)4EYK and EYKEYAEYAAYAEYAEYK were conjugated to biotin as described (27) . Supernatants from cell lines grown in proteinfree serum-free medium (see above) were concentrated 50-200 times on a Centricon-30 filtration system (Amicon) and antigen-binding activity was assessed by a modified ELISA assay (28) . In some experiments, peptides (without biotin) were added at 100 ng to 1 ,ug per well with the active biotinylated peptide to assess competition for binding.
RESULTS
Transer of TCRa from Al.1, With or Without TCRIJ from AM.l, Confers the Ability to Produce the Antigen-Specific Activity. The fine antigenic specificity of the Al.1-derived immunoregulatory activity has been described (12, 13) , and those results that are relevant to the experiments described here are summarized in Table 1 . As shown in Fig. 1 TCRf3 of A1.1. Like A1.1, B9 expresses both TCRa and TCR/8 and produces interleukin 2 in response to the antigen (poly-18) presented with I-Ad (11) . As shown in Fig. 2 , supernatants from AM.1, but not B9, contained the antigenspecific regulatory activity. B9 cells expressing the AM.1 TCRa (B9-Al.la) also produced this activity, whereas those expressing the AM.1 TCRt3 (B9-Al.1,) did not. B9 cells expressing both the TCRa and TCRf3 from A1. 1 (B9-Al .laB) also produced the regulatory activity.
Supernatants of B9-Al.la cells were fractionated by antibody affinity chromatography on immobilized anti-TCRa antibody and tested for antigen-specific regulatory activity by using a panel offour peptides coupled to SRBCs in the assay. As shown in Fig. 3 , the soluble activity from B9-A1.la bound to and was eluted from anti-TCRa. The observed specificity for the unsubstituted peptide and the peptide substituted at amino acid 7 (but not those ofpeptides substituted at residues 3 or 10) is characteristic of the antigen-specific activity from A1.1 (13) (see Table 1 ). As discussed (13) , this specificity correlates with the poly-18 epitope recognized by the AM.1 TCR.
In addition to B9, the Al. Fig. 4 , supernatants from BW1100-A1.la, but not BW1100-Al.1p, displayed immunoregulatory activity. As with the other gene-transfer experiments, this activity showed identical antigenic specificity to that ofAl. 1.
Gene Transfer of A1. 
DISCUSSION
The CD4' T-cell hybridoma A1.1 constitutively releases an immunoregulatory activity specific for the synthetic antigen poly-18 and related peptides (12, 13) . In this paper, we have demonstrated that gene transfer of the A1.1 TCRa gene into other T-cell lines confers the ability to constitutively produce this antigen-specific regulatory activity (Figs. 1-4) . Transfer of the A1.1 TCR/3 neither produced nor interfered with this effect (Fig. 2) . The antigenic specificity of the soluble activity produced by each transduced recipient T-cell line was iden- 3 . Regulatory activity released from B9-A1.la is bound by anti-TCRa and displays the same fine antigenic specificity as the regulatory activity from A1.1. Supernatants from B9-A1.la were fractionated by using hamster anti-mouse TCRa mAb (H28) as described (13) . Filtrate or eluate was added at 10%6 (vol/vol) to assay cultures with the indicated peptide coupled to SRBCs. The resulting pattern of fine antigenic specificity is identical to that of the regulatory activity in A1.1 supernatants (12, 13) . Underlined residues are substitutions in the poly-18 sequence. Reciprocal Dilution of Supernatant   FIG. 4 . Expression of the A1.1 TCRa in cells lacking TCRj is sufficient for production of the antigen-specific regulatory activity. TCRa or TCRT were transferred to BW1100 cells (15) and supernatants were tested for regulatory activity by using either EYK(EYA)4 (A) or (EYA),, (B) coupled to SRBCs. tical to that ofA1.1. This activity was bound by an anti-TCRa mAb (Fig. 3) and the eluted activity displayed the same fine antigenic specificity shown by A1.1 supernatants (13) . It therefore appears that the TCRa is somehow released from A1.1 cells, binds to specific antigen (coupled to SRBCs in our bioassay), and participates in inducing inhibition of the immune response to SRBCs in vitro.
Three lines of evidence suggest that the TCRa from AM.1 is released from the cell in a form that is independent of the CD3-TCR complex. The regulatory activity from AM.1 is bound by anti-TCRa mAb, but not anti-TCR43, anti-TCR VP, or anti-CD3e (13) . Further, antisense oligodeoxynucleotides corresponding to different components of the CD3-TCR complex blocked cell surface CD3 expression but not production of the A1.1-derived activity, whereas antisense oligodeoxynucleotides to TCR Va blocked both (ref. 14 and unpublished observations). Finally, transfer of the A1.1 TCRa gene into BW1100, which lacks TCRf3 (15), nevertheless resulted in constitutive production ofthe antigen-specific regulatory activity (Fig. 4) .
Klausner and colleagues (30) have shown that TCRa is retained and degraded in the endoplasmic reticulum unless complexed with CD38 and further (31) that TCRa that is not exported to the cell surface as part of the CD3-TCR complex is degraded in lysosomes. These observations argue against a pathway whereby TCRa might be released from cells. Recent studies on TCR(3, which is similarly retained and degraded in the endoplasmic reticulum (32) , suggest that the assembly and transport of TCR is more complex. For example, in scid/scid mice expressing a TCRT transgene, TCRfi is clearly expressed on the surface of immature thymocytes in the absence of TCRa or CD3 components (33) . Further, a truncated TCR(3 gene has been constructed, including only the variable-diversity-joining regions (VDJ) and the p1-chain constant domain, and this is secreted despite the expectation that such a molecule should be retained and/or degraded (34) . Thus, the possibility exists that in some cells TCRa might be released in small quantities, possibly in a complex with other unidentified molecules and/or in a posttranslationally truncated form.
We suspect that it is the direct recognition of antigen by the A1.1 TCRa (Fig. 5 ) that gives this molecule activity in the bioassay and that other T cells might release TCRa that fails to bind directly to the antigen and, therefore, does not display such activity. It is possible, for example, that the complex of TCRa and antigen is immunogenic, resulting in regulatory immune responses to the TCR. Recent studies have indicated that immunization with specific T cells (35, 36) or peptides corresponding to regions in the TCR variable region (37, 38) can result in dramatic immunoregulatory effects in vivo, and it is, therefore, possible that the regulatory effects associated with the AM.1 TCRa might represent a form of such TCR "vaccination" in vitro. Table 1 for complete sequences) were added at the indicated concentrations to supernatant-coated plastic plates at the same time as the addition of EYK(EYA)4EYK-biotin and binding of the biotinylated peptide was assessed by A410. Alternatively, it may be that an unidentified molecule associates with the antigen-binding TCRa and this second molecule imparts biological function to the system. For example, Iwata et al. (39) have described a soluble complex of a molecule with glycosylation-inhibitory activity and a molecule bearing TCR determinants released into supernatants of some T-cell hybridomas. Their data are consistent with the possibility that the TCRa imparts antigen specificity and an associated antigen-nonspecific molecule determines biological function.
It is interesting that a number of antigen-specific T-cellderived factors, capable of regulating immune responses in vitro and in vivo, show a relationship to TCRa. Taniguchi and colleagues (40) were the first to demonstrate that TCRa is rearranged and expressed in T-cell hybridomas producing such factors and they found a strong correlation between production of a keyhole limpet hemocyanin-specific factor and expression of a particular VaJa combination in the T cells (41) . Collins et al. (42) have found that T-cell hybridomas that produce factors capable of suppressing immune responses to the hapten nitrophenol express TCRa, and this expression of TCRa, but not that of TCRI3, is a requirement for production of the hapten-specific factor. Thus, subclones of a factor-producing T-cell hybridoma that had lost TCRF (and cell surface TCR expression) nevertheless produced the regulatory factor (42), whereas clones that had lost TCRa were unable to produce the factor (V. K. Kuchroo, M. Collins, and M. Dorf, personal communication). Further, they have recently found that transfection of the original TCRa chain into such TCRa-variants restored the ability to produce the factor (V. K. Kuchroo, M. Byrne, M. Collins, and M. Dorf, personal communication). Similarly, a number of laboratories (10, 39, 43) have reported that the antigenspecific component of various T-cetl-derived antigen-specific regulatory factors is bound by the anti-TCRa mAb we have used in our studies (ref. 13 and Fig. 3) . Since the A1.1 TCRa appears to induce an immunoregulatory activity in vitro, it is possible that other TCRa chains are functional as components of antigen-specific factors with in vivo immunoregulatory activity. If so, this would suggest that our findings may have general implications for the control of immune responses.
